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Current limitations of recombinant tissue-type plasminogen 
activator (r&PA) therapy for acute myocardial infarction 
include failure to achieve recanalization in 25% of patients, 
reocclusion and reperfnsion injury. Iloprost, a stable ana- 
logue of prostacyclin (PGI,), has been demonstrated to 
facilitate thrombolysis and reduce myocardial stunning 
in experimental models. To evaluate combined therapy, 
r&PA (100 mg 3 h) and Iloprost (2 nglkg per min for 
48 h) were administered to 25 patients and then r&PA 
alone (same dose) was given to an additional 25 patients 
with evolving myocardial infarction. At 90 min after 
drug administration, infarct-related vessel patency was 
observed in I1 (44%) of 25 who received rt-PA plus 
Iloprost compared with 15 (60%) of 25 who received r&PA 
alone (p = 0.26). At 1 week, reocclusion had occurred in 
3 (14%) of 21 patients who received combined therapy 
compared with 6 (26%) of 23 patients treated with rt-PA 
alone (p = 0.46). 
Ejection fraction increased significantly from baseline to 
7 days for r&PA alone whereas it decreased with combined 
therapy (&PA alone: 47.3 -t 11.5% at baseline to 50.4 + 
9.8% at 7 days; rt-PA plus Iloprost: 51.3 + 10.1% at 
baseline to 49.0 + 9.4% at 7 days; difference between groups 
p = 0.05). At 4 h after therapy, fibrinogen decreased 33% 
for r&PA plus Iloprost compared with a 52% for r&PA alone 
(p = 0.001). Fibrinogen degradation products increased 
60% more for r&PA alone than for rt-PA plus Iloprost. 
Thus, the combination of &PA plus Iloprost at the doses 
employed did not improve immediate or follow-up coronary 
artery patency or left ventricular functional recovery com- 
pared with that achieved with &PA alone. 
(J Am Co11 Cardiol1989;14:877-84) 
There is abundant experimental evidence that intravenous 
prostacyclin administration has a beneficial effect in myocar- 
dial infarction. Prostacyclin (PGI,) has been demonstrated to 
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reduce infarct size (l-6), inhibit oxygen free radical forma- 
tion (7,8) and neutrophil function (9), thereby reducing 
reperfusion injury and myocardial stunning (10). Besides 
these important actions at the tissue and myocyte levels, 
prostacyclin is both the most potent endogenous platelet 
inhibitor known, capable of producing active platelet disag- 
gregation, and a relatively strong systemic and coronary 
artery vasodilator (11). These latter properties account for 
its acceleration of thrombolysis (12), potential to sustain 
infarct-related vessel patency, reduction in preload and 
afterload and improvement in collateral and infarct-related 
vessel blood flow (1,2,11). 
Intravenous tissue-type plasminogen activator @-PA) 
has been shown to be an effective coronary thrombolytic 
agent, achieving recanalization of the infarct-related artery 
in 75% of patients (13-15), improving cardiac function (16- 
0735-10971891$3.50 
878 TOPOL ET AL. JACC Vol. 14, No. 4 
PROSTACYCLIN AND rt-PA FOR MYOCARDIAL INFARCTION October 1989:877-84 
19) and decreasing mortality rate in the acute phase of 
infarction (19). However, approximately 25% of patients 
(20,21) fail to achieve coronary artery recanalization within 
90 min of administration of rt-PA, and the drug requires >45 
min on average to be effective (13,14,22). Reocclusion is not 
infrequent, ranging from 13% to 33% without mechanical 
intervention (13,15,22-25), and improvement in left ventric- 
ular function has been modest (15-19,25). Thus, several of 
the major deficiencies of coronary thrombolytic therapy with 
rt-PA might hypothetically be compensated for or avoided 
by combined treatment with prostacyclin. In this pilot study, 
we evaluated the combination of rt-PA and a stable analogue 
of prostacyclin, Iloprost, in patients with evolving myocar- 
dial infarction. Our goal was to demonstrate the potential for 
this combination to facilitate infarct-related vessel patency, 
reduce the frequency of reocclusion and recurrent ischemic 
events and improve cardiac function. 
Methods 
Study patients. Patients at two clinical sites were enrolled 
from September 24, 1987 to March 1, 1988. Entry criteria 
included chest discomfort of 220 min but <6 h duration, 
electrocardiographic (ECG) ST segment elevation rl mm in 
two or more contiguous leads, age 575 years, no previous 
myocardial infarction in the same territory and no contrain- 
dication to thrombolytic therapy, as detailed in previous 
Thrombolysis and Angioplasty in Acute Myocardial Infarc- 
tion (TAMI) protocols (25,26). The protocol was approved 
by the institutional review boards at the participating insti- 
tutions, and patients gave informed consent before enroll- 
ment. 
Protocol. For a pilot study, we planned to treat 25 
patients with ‘combined &PA and Iloprost. After the pa- 
tient’s enrollment, one intravenous line was started in each 
forearm and the medications were reconstituted. Predomi- 
nantly single chain rt-PA (13) (Genentech, Inc.) was admin- 
istered in a dose of 1 mglkg body weight for the first h, with 
a maximal dose of 80 mg, and 10% of this dose was given as 
a bolus. The balance of the 100 mg dose was infused at a 
constant rate over the next 2 h. Iloprost was initially infused 
intravenously at a dose of 0.5 ng/kg per min. The dose was 
increased at 5 min intervals to 1 ng/kg per min and to 2 ng/kg 
per min, and was then kept constant for 48 h, provided that 
the patient’s blood pressure was stable and >85 mm Hg and 
no serious side effects occurred. For the treatment of hypo- 
tension, intravenous hydration was used before tapering or 
discontinuing the Iloprost. One hour before discontinuation 
of Iloprost, the infusion was gradually tapered to avoid the 
effect of sudden cessation of the drug. 
After initiation of therapy, patients were transferred to 
the cardiac catheterization laboratory for angiographic de- 
termination of patency of the infarct-related vessel and 
baseline left ventricular function. After arterial access had 
been obtained, heparin, 5,000 U, was administered intrave- 
nously. A single contrast injection into the infarct-related 
artery was performed at 60 min after therapy if possible. The 
primary end point of infarct-related vessel patency was 
determined at 90 min after therapy, utilizing up to four 
contrast injections of the vessel in multiple orthogonal 
hemiaxial views. Angiography of the noninfarct-related cor- 
onary arteries and the left ventricle was also performed. 
If the infarct-related vessel was demonstrated to be 
patent (TIM1 grade 2 or 3 flow) (15,22,24), no coronary 
angioplasty was performed during the immediate cardiac 
catheterization. Patients whose infarct-related vessel was 
occluded at 90 min after therapy (TIM1 grade 0 or 1 flow) 
underwent “rescue” coronary angioplasty (26). 
After transfer to the coronary care unit, patients were 
treated with oral aspirin (5 grains/day) and heparin (1,000 
U/h) for at least 72 h, the dose adjusted to maintain the 
partial thromboplastin time at 2 to 2.5 times the normal 
value. Lidocaine was given prophylactically as a 75 mg bolus 
and 1 to 2 mgimin infusion during the first 24 h. Beta- 
adrenergic blockers, calcium channel blockers and nitrates 
were not given unless specifically required to treat ischemia, 
hypertension or rhythm disturbances. 
At 7 days, patients returned to the cardiac catheterization 
laboratory for repeat left ventriculography and coronary 
angiography. If an interim event of recurrent ischemia had 
occurred, defined as ~20 min of chest discomfort, unre- 
lieved by nitroglycerin and accompanied by ECG changes, 
patients underwent emergency coronary angiography. In 
these patients, a third cardiac catheterization was performed 
before hospital discharge. After 25 patients were treated 
with rt-PA and Iloprost, the decision was made to treat an 
additional 25 patients with rt-PA alone but otherwise employ 
the identical protocol. The decision was based on the con- 
cern regarding the negative data obtained for combined 
therapy, as described later, which included a low infarct- 
related vessel patency rate, high abrupt closure frequency 
after rescue coronary angioplasty and minimal recovery of 
left ventricular function. 
Angiographic studies. Cineangiographic films were for- 
warded to a core angiographic laboratory for blinded review 
by a single observer to determine infarct-related vessel TIM1 
flow grade (22), percent diameter stenosis by quantitative 
angiography (27) and left ventricular function. Technically 
inadequate studies due to inadequate opacification or exces- 
sive extrasystoles were deleted from analyses. Quantitative 
percent diameter and absolute diameter stenosis were deter- 
mined with use of a computerized automatic edge detection 
algorithm (27). Global ejection fraction was determined by 
the area-length method (28) and regional wall motion of the 
infarct and noninfarct zones by the centerline chord method 
(29). 
Assays of the hemostatic and fihrinolytic system. Blood 
samples were collected on 0.01 M citrate at baseline and 4, 
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Table 1. Baseline Characteristics of the 50 Patients 
No. of patients 
Age (yr) 
Gender (no.) 
Weight (kg) 
Time from chest pain to 
therapy (h) 
rt-PA t Iloprost 
2s 
51.0 ? 11.5 
l9M, 6F 
79.2 2 3.3 
3.4 ? 0.3 
r&PA Alone 
2s 
56.6 2 8.1 
19M. 6F 
81.0 + 2.8 
2.1 5 0.2 
Infarct-related vessel (no.) 
LAD 10 (40%) 1 I (44%) 
LCX 3 (12%) I (4%) 
RCA 12 (48%) I? (48%) 
SVG 0 1 (4%) 
SBP at entry (mm Hg) 128.2 + 25.4 132.8 + 18.9 
HR at entry (beatsimin) 74.0 + 18.2 75.2 ? 17.6 
F = female; HR = heart rate; LAD = left anterior descending coronary 
artery; LCx = left circumflex coronary artery; M = male: RCA = right 
coronary artery; r&PA = recombinant tissue-type plasminogen activator: 
SBP = systolic blood pressure: SK = saphenous vein graft. 
12, 24 and 48 h after the initiation of rt-PA therapy. The 4 h 
sample also contained 200 KIU/ml of aprotinin to minimize 
in vitro fibrinolytic artifact. Samples were processed as 
previously described (30). Briefly, after immediate centrifu- 
gation for harvesting of plasma, samples were kept frozen at 
-20°C until assayed for fibrinogen by a coagulation rate 
assay (31) and for fibrinogen degradation products by agglu- 
tination inhibition of tanned red blood cells (32). The rt-PA 
plasma level at 4 h after therapy was measured by antigenic 
assay (30). 
Data analysis. Data are expressed as mean values t SD, 
unless otherwise stipulated. The differences for infarct- 
related vessel patency, reocclusion and side effects were 
compared by chi-square test or, if the expected cell size was 
<5, Fisher’s exact test. Serial studies of left ventricular 
function by contrast ventriculography were evaluated by 
paired t test for intragroup comparison and unpaired t test 
for comparison between groups. The changes in fibrinogen 
degradation products were compared with use of a Wilcoxon 
signed-rank test. 
Results 
Patient characteristics. The baseline demographic, angio- 
graphic and hemodynamic variables are presented in Table 
1. One additional patient received r&PA and Iloprost but was 
subsequently deleted from the analysis because of a lack of 
confirmation of myocardial infarction by serum enzyme or 
ECG criteria. Angiography in this patient demonstrated 
normal coronary arteries. 
The two treatment groups were comparable except for a 
0.7 h delay in therapy in the combined rt-PA and Iloprost 
group, which was accounted for in part by the protracted 
preparation time required to reconstitute this medication (2 
Patency (95% C.1.l 
??I-PA 8 lloprost 44% (24,65) 
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Figure 1. Infarct-related vessel patency by Thrombolysis in Myo- 
cardial Infarction (TIMI) grade in the two treatment groups. The 
95% confidence limits ((2.1.) for the two treatment regimens are 
demonstrated to be overlapping. 
mg vials). Infarct-related vessel patency at 90 min occurred 
in 1 I (44%) of the 25 rt-PA plus Iloprost-treated patients and 
15 (60%) of the 25 patients treated with rt-PA alone (p = 
0.26) (Fig. 1). 
Clinical course and outcome (Tables 2 and 3). Early 
infarct-related vessel patency was established in 21 patients 
who received rt-PA plus Iloprost therapy and in 23 patients 
who were treated with rt-PA alone. Patency was demon- 
strated during the course of the four serial coronary angio- 
grams in three patients receiving combined therapy com- 
pared with one who received rt-PA alone. Reocclusion was 
subclassified as occurring after pharmacologic reperfusion 
after mechanical (balloon angioplasty) intervention and ac- 
cording to when it occurred (Table 2). There were no 
significant differences for reocclusive episodes between the 
two patient groups, particularly when abrupt closures in the 
cardiac catheterization laboratory were considered. After 
discharge from the laboratory, the decreased frequency of 
reocclusion in patients receiving combined therapy was 
related to pharmacologic reperfusion. 
There were no in-hospital deaths. The adverse events 
possibly related to drug therapy and bleeding complications 
are presented in Table 3. The patients treated with combined 
rt-PA and Iloprost had an excess of severe nausea and 
vomiting (p = 0.001). Significant hypotension led to tapering 
of Iloprost dosage in five patients and discontinuation in an 
additional three patients. As expected, there was a more 
significant overall decrease in blood pressure and reflex 
tachycardia in the patients who received combined therapy. 
The transfusion requirement was similar for the two groups, 
and the combined rt-PA and Iloprost therapy did not lead to 
an increased frequency of bleeding complications. 
Left ventricular function. Global and regional left ven- 
tricular function results at baseline and 7 days are shown in 
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Table 2. Clinical and Angiographic Outcomes in the Two 
Treatment Groups 
&PA = lloprost rt-PA Alone 
(n = 25) (n = 25) 
Coronary artery patency 
First 90 min injection 11 (44%) 15 (60%) 
Final diagnostic injection 14 (56%) 16 (64%) 
At end of procedure* 21 (84%) 23 (92%) 
Abrupt closure in 5 (24%) 2 (9%) 
laboratoryt 
Reocclusion$ 3 (14%) 6 (26%) 
Reocclusion after lysis only 1114 (7%) 4116 (25%) 
Reocclusion after PTCA 2/7 (29%) 217 (29%) 
Emergency CABG 1 (4%) 1(4%) 
Death 0 0 
*Denotes that the patient was discharged from the cardiac catheterization 
laboratory with a patent infarct-related vessel (TIM1 grade 2 or 3 flow 
pattern). tDenotes the transient cessation of infarct-related vessel flow (TIM1 
grade 0) after rescue angioplasty, requiring repeat balloon dilation. fDefined 
as an angiographically confirmed event after the patient was discharged from 
the cardiac catheterization laboratory. CABG = coronary artery bypass 
grafting; FTCA = percutaneous transluminal coronary angioplasty; rt-PA = 
recombinant tissue-type plasminogen activator. 
Figures 2 and 3, respectively. In 25 patients treated with 
rt-PA plus Iloprost, baseline ejection fraction was 51.3 + 
lO.l%, infarct zone wall motion, expressed as standard 
deviation (SD) per chord, was -2.73 + 0.92 SD/chord and 
noninfarct zone wall motion was 1.31 -+ 1.09 SD/chord. At 
follow-up study in 23 patients, ejection fraction was 49.0 t 
9.4%, infarct zone wall motion was -2.58 2 0.93 SD/chord 
and noninfarct zone wall motion was 0.61 -+ 1.08 SD/chord. 
Ejection fraction in 23 paired studies decreased 1.8 + 5.3 
percentage points (p = 0.12), and infarct zone wall motion 
did not significantly improve (0.21 -t 0.90 SD/chord, p = 
Table 3. Side Effects in the 50 Patients 
r&PA = Iloprost &PA Alone 
(n = 25) (n = 25) p Value 
Flushing 3 (12%) I (4%) 
Headache 8 (32%) 4 (16%) 
Bleeding (~2 U) 5 (20%) 5 (20%) 
Nausea/vomiting* 19 (76%) 7 (28%) 0.001 
Antiemetic use 13 (54%) 4 (18%) 0.08 
Vomiting I6 (67%) 7 (30%) 0.02 
SBP (4 h) 
mm Hg 113 + 19 122 k 21 <O.OOl 
% change 12.5% 1 7%1 
HR (4 h) 
beats/min 85 + 12 802 15 
% change 13% t 6% t 
*Defined as protracted nausea and vomiting lasting >I h documented in 
the medical record. r&PA = recombinant tissue-type plasminogen activator; 
t = increase; 4 = decrease; SBP = systolic blood pressure. 
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Figure 2. Effects of rt-PA and Iloprost versus rt-PA alone on 
recovery of global left ventricular function. The baseline and 7 day 
ejection fractions (left y axis) are plotted, as is the change (A) in 
ejection fraction (right y axis). Note the significant difference (4 in 
recovery of ejection fraction between the two interventions (p = 
0.05). 
0.28). Noninfarct zone wall motion regressed significantly 
(0.69 t 0.74 SD/chord, p < 0.001). 
For 24 patients who received rt-PA alone, baseline global 
ejection fraction was 47.3 + 11.5%, infarct zone wall motion 
was -3.03 ? 0.56 SD/chord and noninfarct zone wall motion 
was 1.52 + 1.9 SD/chord. At the 7 day repeat study, the 
Figure 3. Regional wall motion of the infarct zone expressed as 
standard deviation (SD) per chord using the centerline chord method 
(29). The patients receiving rt-PA alone had significant improvement 
in regional wall motion; those receiving rt-PA plus Iloprost had a 
slight but statistically insignificant improvement. The absolute im- 
provement (A) from baseline to 7 day study of wall motion was 
three-fold higher for patients receiving &PA alone compared with 
those receiving the combination. 
2 1 ??t-PA and lloprost ??t-PA 1 0.76 
p - 0.26 
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ventriculograms obtained in six of these patients were not 
technically adequate for analysis and one patient refused 
repeat cardiac catheterization. At follow-up study in 18 
patients, ejection fraction was 50.4 ? 9.8%. infarct zone wall 
motion was -2.13 2 1.05 SD/chord and noninfarct zone wall 
motion was 0.72 ? 1.67. In 18 paired studies, ejection 
fraction increased 2.3 ? 7.9 percentage points (p = 0.22). 
infarct zone wall motion improved 0.76 ? 0.89 SD/chord 
(p = 0.002) and noninfarct zone wall motion regressed 1.09 
t- 1.39 (p = 0.004). The recovery in ejection fraction, as 
measured by the difference from baseline to follow-up study, 
was reduced for combined rt-PA and Iloprost compared with 
rt-PA alone (p = 0.05) and infarct zone wall motion recovery 
was also diminished with combination therapy (p = 0.05). 
When on1.v patients in whom pharmacologic reperfusion 
Cut-PA plus Iloprost or rt-PA alone) was successful were 
considered, the same trends for a decreased recovery of left 
ventricular function in the combined rt-PA and Iloprost 
treatment group were observed. For patients with an open 
infarct-related vessel at early catheterization and paired, 
technically adequate ventriculographic studies, the median 
ejection fraction at 90 min of therapy was 48.5% for 14 
patients receiving rt-PA plus Iloprost and 48.5% for 16 
patients who received rt-PA alone. At 7 days, the ejection 
fraction was 48.5% and 52.0%, respectively. Regional wall 
motion of the infarct zone at 90 min for the two groups was 
-2.96 SD/chord and -3.07 SD/chord for combined therapy 
and rt-PA alone groups, respectively. At follow-up study, 
the median values were -2.89 SD/chord and -2.05 SD/ 
chord, respectively. This represents no improvement for the 
combined treatment group but a 33% recovery of regional 
function in the patients receiving rt-PA alone. 
Quantitative coronary angiography. Technically ade- 
quate paired quantitative coronary angiographic data with- 
out total occlusion were available in 13 patients who re- 
ceived rt-PA plus Iloprost and 14 patients treated with rt-PA 
alone. Patients with an occluded infarct-related artery at 
initial cardiac catheterization (6 patients) or those with at 
least one inadequate study for quantitative analysis (11 
patients) were excluded. The absolute mean diameter in- 
creased from 0.68 of: 0.64 mm at baseline to 0.84 ? 0.54 mm 
at 7 days for rt-PA plus Iloprost compared with 0.93 t 0.44 
to 0.87 + 0.67 mm, respectively, for rt-PA alone. The 
baseline and follow-up quantitative infarct-related vessel 
stenosis rates were not significantly different between the 
groups (p = 0.24 and 0.89. respectively). Over the 7 days, 
percent diameter stenosis decreased from 78.9 t 17.3% to 
71.1 z 18.0% for patients treated with rt-PA plus Iloprost 
and increased slightly from 71 .O 5 13.2% to 72.9 2 19.9% for 
patients receiving rt-PA alone. 
Effects on hemostasis and fihrinolysis. The effects of the 
treatment regimen on fibrinogen and fibrinogen degradation 
products are summarized in Table 4. Of note, the baseline 
fibrinogen level was higher in the patients receiving rt-PA 
Table 4. Effect on Hemostatic Variables in the Two 
Treatment Groups 
No. of patients 
Fibrinogen (mgidl) 
IT-PA t lloprost 
25 
rt-PA Alone 
19* 
Baseline 
4 h (% change) 
12 h (‘ST change) 
FDP 
2.70 + 0.52 3.45 ? 1.07 
1.79 + 0.65 (33%)** 1.65 -+ 0.89 (52%)t 
2.09 _c 0.58 (22%) I .60 2 0.98 (53%) 
Baseline 0 0 
4 h titer (median) 0: lOO$ 
I.! h titer (median) 5$ 33$ 
ri-PA antigen (4 h) &/ml) 547.4 + 689.9 406 + 314.3 
*Six patients in the &PA group who subsequently received urokinase 
were deleted from this analysis. tp = 0.001 I. $p < 0.005 by Wilcoxon 
analysis. FDP = fibrinogen degradation products; IT-PA = recombinant tissue 
plasminogen activator. 
alone. In addition, the decline in fibrinogen and development 
of fibrinogen degradation products over 12 h was signifi- 
cantly greater in this group. The plasma rt-PA levels at 4 h 
after initiation of therapy were highly variable, but were not 
found to be lower in the patients treated with &PA alone; 
peak samples were not obtained. 
Discussion 
Lack of enhancement of thrombolysis with Iloprost. Al- 
though this study was relatively small, sequential and a pilot 
study by design, our findings raise several issues that must 
be considered in the development of new adjunctive phar- 
macologic strategies for the treatment of acute myocardial 
infarction. First, we tested an agent, Iloprost, which holds 
much promise for enhancing thrombolysis, sustained infarct- 
related vessel patency and ventricular functional recovery 
(9,10.12). The combination of rt-PA and this prostacyclin 
analogue led to disappointing results, with an overall low 
coronary artery patency rate and less recovery of ventricular 
function than that obtained with treatment with rt-PA alone. 
As these findings were investigated, we noted substantially 
less degradation of the hemostatic proteins by rt-PA plus 
Iloprost. Unfortunately, peak plasma r&PA levels (50 to 60 
min after therapy) were not obtained in the current study. 
Recently, Kerins et al. (33) demonstrated that under exper- 
imental steady state plasma conditions of exogenously ad- 
ministered rt-PA, an infusion of Iloprost led to an abrupt 
31% reduction in the plasma rt-PA level, which promptly 
reverted to steady state levels after cessation of Iloprost. 
Their study corroborates the clinical findings that we ob- 
served, and together these studies support the possibility of 
an in vivo pharmacokinetic interaction. The precise mecha- 
nism for such an interaction has not been elucidated, but 
likely involves Iloprost’s effect of increased hepatic blood 
flow and potential secondary accelerated clearance of rt-PA. 
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Nonetheless, our results point out the importance of per- 
forming careful experimental pharmacokinetic testing of new 
drug combinations in this setting before their introduction to 
patients with acute myocardial infarction. 
Lack of improvement in ventricular function. Second, at 
the maximal dose generally tolerated of Iloprost (2 nglkg per 
min) in our clinical study, there was no evidence of improve- 
ment in ventricular function, even in patients with a patent 
infarct-related vessel throughout their hospitalization. Pre- 
vious experimental studies (9,10,34) suggest that at doses of 
Iloprost ranging from 5 to 20 ng/kg per min, reperfusion 
injury and myocardial stunning can be markedly abated by 
inhibition of neutrophil activity. The current study repre- 
sents the first clinical study of thrombolytic therapy coupled 
with an agent purported to reduce reperfusion injury. In our 
study, the two agents were administered simultaneously, 
providing an ample concentration of Iloprost to be present 
before reperfusion was achieved, and the infusion was 
continued for 48 h. These negative results in terms of no 
potentiation of ventricular function and our inability to 
replicate the data obtained in the experimental setting may 
be due to inadequate doses of Iloprost administered relative 
to the studies cited or to inability to inhibit reperfusion injury 
in the clinical setting. With respect to the potential of 
inadequate dosing, it is unlikely that most patients can 
tolerate even higher doses of Iloprost, because several 
patients in the current study experienced either significant 
hypotension or severe nausea and vomiting. Furthermore, 
we observed a hemodynamic effect of Iloprost with respect 
to lowering systolic blood pressure. The decrease in after- 
load in the acute phase may have led to a higher initial 
ejection fraction, thus reducing the chance to demonstrate 
recovery of left ventricular function. 
Lack of prevention of reocclusion. Third, reocclusion 
occurred despite the maintenance infusion of Iloprost. Al- 
though experimental studies have demonstrated Iloprost’s 
potent platelet disaggregative properties (35,36), and reoc- 
elusion after thrombolysis may be partially a platelet- 
mediated event (37), several patients in our study experi- 
enced abrupt coronary artery closure while in the cardiac 
catheterization laboratory. These reocclusive episodes oc- 
curred in the setting of concomitant Iloprost therapy, intra- 
venous heparin infusion, aspirin administration and recent or 
ongoing rt-PA therapy. Recently, Yasuda and Gold and 
colleagues (38,39) studied combined rt-PA and the platelet 
(7E3) monoclonal antibody to the glycoprotein IIAlIIIB 
receptor. These investigators demonstrated that, in the 
experimental model, reocclusion could be abolished at cer- 
tain dose combinations. Similarly, acceleration of coronary 
artery recanalization was shown with combined throm- 
bolytic and platelet antagonist therapy compared with rt-PA 
alone. Although we were unable to determine the extent of in 
vivo platelet inhibition in our patients, previous clinical 
studies (40) have demonstrated marked disaggregation with 
the doses of Iloprost employed. However, in vitro experi- 
ments (41) with rt-PA and Iloprost have demonstrated less 
antiplatelet effect with the combination compared with rt-PA 
alone. Certainly, in the current study, the stimulus for 
reocclusion was not substantially reduced by this prostacy- 
clin analogue. From such experiments and our clinical 
observations, it appears that the process of thrombolysis 
may actually serve a platelet-stimulating role (42,43). Fur- 
thermore, the infarct-related vessel patency rate was not 
high or accelerated compared with that with rt-PA alone. In 
both treatment groups, a low patency rate was demonstrated 
compared with that in several clinical trials testing the same 
dose of this predominantly single chain rt-PA preparation. 
However, because of the small sample size, the confidence 
intervals for patency are especially wide (Fig. 1). 
Conclusions. Recent large scale clinical trials (17-20) 
have emphasized the fundamental value of thrombolytic 
therapy for improved survival and ventricular function and 
reduction in infarct size. In the Second International Study 
of Infarct Survival (ISIS-2) (44), the importance of early 
treatment with aspirin in conjunction with streptokinase for 
mortality reduction was clearly demonstrated. The role of 
other adjunctive pharmacologic agents to coronary throm- 
bolysis is the focus of many ongoing clinical trials. Our 
results suggest that at the maximal clinically tolerated dose 
of Iloprost, ventricular functional recovery is not aug- 
mented. Although the potential rt-PA and Iloprost in vivo 
pharmacokinetic interaction may be overridden by increased 
rt-PA dosing, this may not be achieved without compromis- 
ing patient safety (45). The negative findings of our pilot 
study should not be generalized to other prostacyclin ana- 
logues or other thrombolytic enzymes (46). More experimen- 
tal and clinical investigation will be necessary for coupling 
thrombolytic therapy and prostacyclin or other agents that 
antagonize platelet function or potentially limit reperfusion 
injury. 
Appendix 
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eleson. MD. Constance Dovle. MD. Patricia Lamb. MD. 
Riverside Methodist f&pit& Barry S. George, MD, Richard J. Candela, 
MD, Joanne Dillon, RN, BS, Ronald D. Frazier, MD, Ramona Masek, RN, 
BS, Ann Pickel, RN. 
Duke University Biostatistical Core Laboratory: Kerry L. Lee, PhD, Lynne 
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Data Monitoring Committee: Mark Hlatkv. MD. Daniel B. Mark, MD, 
MPH, Kerry L. Lee, PhD. 
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